Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Sees Generic Competition for Cymbalta (x6)

By Brian Orelli, PhD - Dec 11, 2013 at 7:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dr. Reddy's Laboratories, Teva Pharmaceuticals, and others gain FDA approval for generic versions of Eli Lilly's Cymbalta.

As expected, the Food and Drug Administration has approved the first generic versions of Eli Lilly's (LLY 0.15%) depression drug Cymbalta.

Six versions in fact.

On Wednesday, Aurobindo Pharma, Dr. Reddy's Laboratories (RDY 0.81%), Lupin, Sun Pharmaceuticals, Teva Pharmaceuticals (TEVA 4.92%), and Torrent Pharmaceuticals all got the FDA's green light to sell the drug known generically as duloxetine.

Given the large number of generic versions, the companies are going to have to compete on price, leading to limited profits for the generic-drug makers and a sharp drop in sales of the branded product.

U.S. sales of Cymbalta were $1.1 billion in the third quarter. Despite the expiration coming toward the end of the quarter, the pharma expects U.S. sales will drop to just $500 million this quarter. Since the expiration of the U.S. patent exclusivity was widely known, wholesalers and retail pharmacies have likely reduced inventories in anticipation of the launches of the generic versions. Eli Lilly's estimated sales also includes expected returns of the product.

While the drop in sales of Eli Lilly's top-selling drug will affect revenue and profits, the exact date for the loss of exclusivity has been known for years and thus shouldn't affect the company's valuation at this point.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$324.71 (0.15%) $0.48
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.89 (4.92%) $0.37
Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
$55.84 (0.81%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.